Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study.

Journal: The Lancet. Digital health
Published Date: Oct 20, 2021

Abstract

BACKGROUND: Gadolinium-based contrast agents (GBCAs) are widely used to enhance tissue contrast during MRI scans and play a crucial role in the management of patients with cancer. However, studies have shown gadolinium deposition in the brain after repeated GBCA administration with yet unknown clinical significance. We aimed to assess the feasibility and diagnostic value of synthetic post-contrast T1-weighted MRI generated from pre-contrast MRI sequences through deep convolutional neural networks (dCNN) for tumour response assessment in neuro-oncology.

Authors

  • Chandrakanth Jayachandran Preetha
    Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Hagen Meredig
    Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Gianluca Brugnara
    Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Mustafa A Mahmutoglu
    Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Martha Foltyn
    Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Fabian Isensee
  • Tobias Kessler
    Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Irada Pflüger
    Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Marianne Schell
    Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Ulf Neuberger
    Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Jens Petersen
    Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany; Medical Image Computing, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Antje Wick
    Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany.
  • Sabine Heiland
    Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Jürgen Debus
    Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; Heidelberg Institute of Radiation Oncology, Heidelberg, Germany; Heidelberg Ion-Beam Therapy Center, Heidelberg, Germany.
  • Michael Platten
    Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Neurology, Mannheim Medical Center, University of Heidelberg, Mannheim, Germany.
  • Ahmed Idbaih
    Sorbonne Université, INSERM U1127, CNRS UMR7225, Institut du Cerveau et de la Moelle épinière (ICM), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France shair@hadassah.org.il ahmed.idbaih@aphp.fr.
  • Alba A Brandes
    Department of Medical Oncology, Azienda USL of Bologna, Bologna, Italy.
  • Frank Winkler
    Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany; Clinical Cooperation Unit Neurooncology, German Cancer Research Center, Heidelberg, Germany.
  • Martin J van den Bent
    Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • Burt Nabors
    Department of Neurology and O'Neal Comprehensive Cancer Center, Division of Neuro-Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Roger Stupp
    Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Department of Neurological Surgery and Department of Neurology, Northwestern Medicine and Northwestern University, Chicago, IL, USA.
  • Klaus H Maier-Hein
    Medical Image Computing (MIC), German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: k.maier-hein@dkfz.de.
  • Thierry Gorlia
    European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
  • Jörg-Christian Tonn
    Department of Neurosurgery, Ludwig-Maximilians-University Munich, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Michael Weller
    Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
  • Wolfgang Wick
    Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Martin Bendszus
    Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Philipp Vollmuth
    Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany. Electronic address: philipp.vollmuth@med.uni-heidelberg.de.

Keywords

External Resources

Popular Topics
Recent Journals